Breaking Down SG&A Expenses: argenx SE vs Intra-Cellular Therapies, Inc.

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestamp	Intra-Cellular Therapies, Inc.	argenx SE
Wednesday, January 1, 2014	10337679	4241601.57
Thursday, January 1, 2015	18187286	5392385.38
Friday, January 1, 2016	24758063	7370036.73
Sunday, January 1, 2017	23666957	14970357
Monday, January 1, 2018	30099855	31413266
Tuesday, January 1, 2019	64947625	72279461
Wednesday, January 1, 2020	186363444	183907682
Friday, January 1, 2021	272611040	307644000
Saturday, January 1, 2022	358782000	472132000
Sunday, January 1, 2023	409864000	709539000

Unveiling the hidden dimensions of data

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: argenx SE and Intra-Cellular Therapies, Inc., from 2014 to 2023. Over this period, argenx SE's SG&A expenses surged by an impressive 16,600%, peaking in 2023. In contrast, Intra-Cellular Therapies, Inc. experienced a 3,900% increase, highlighting a more conservative growth trajectory.

Key Insights

argenx SE: Witnessed a dramatic rise in SG&A expenses, particularly from 2021 onwards, reflecting its aggressive expansion and investment in administrative capabilities.
Intra-Cellular Therapies, Inc.: Showed steady growth, with a notable spike in 2023, indicating strategic scaling efforts.

This financial journey underscores the dynamic strategies employed by these biotech giants in navigating the ever-evolving market landscape.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Breaking Down SG&A Expenses: Johnson & Johnson vs Intra-Cellular Therapies, Inc.

SG&A Efficiency Analysis: Comparing Novartis AG and Intra-Cellular Therapies, Inc.

Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc. Trends and Insights

Selling, General, and Administrative Costs: argenx SE vs Biogen Inc.

Selling, General, and Administrative Costs: argenx SE vs Verona Pharma plc

Comparing SG&A Expenses: argenx SE vs Veracyte, Inc. Trends and Insights

Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited: SG&A Spending Patterns Compared

Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Catalent, Inc.

Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends

Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends